Stay updated on Pembrolizumab and TKI in CML MRD Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and TKI in CML MRD Clinical Trial page.
Latest updates to the Pembrolizumab and TKI in CML MRD Clinical Trial page
- Check6 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%
- Check13 days agoChange DetectedAdded updated study-record timestamps (e.g., last update posted and last update submitted) and removed older timestamps; no changes to trial details or criteria.SummaryDifference0.1%
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedAdded Revision: v3.4.2. Removed the government funding operating status notice and Revision: v3.4.1.SummaryDifference0.1%
- Check41 days agoChange DetectedAdded a site-wide notice about a lapse in government funding and updated the revision from v3.4.0 to v3.4.1.SummaryDifference0.1%
- Check48 days agoChange DetectedAdded a Show glossary option and updated revision metadata (Last Update Posted 2026-01-23, Last Update that Met QC Criteria 2026-01-26) to revision v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check70 days agoChange DetectedRecent changes are administrative updates to the study record dates (December 2025 and November 2025). They do not modify core study information such as eligibility, interventions, outcomes, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab and TKI in CML MRD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and TKI in CML MRD Clinical Trial page.